Legend Biotech (STU:9LB) FFO per Share

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:9LB Legend Biotech Corp STU:9LB
75 GF Score
Price €20.60
GF Value €86.66
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Legend Biotech FFO per Share?

FFO per Share only applies to REITs.

STU:9LB
75GF Score
Legend Biotech Corp STU:9LB
FFO per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Legend Biotech (STU:9LB) Overvalued in 2026?

Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued. The current stock price of €20.60 is trading 76.2% below its estimated GF Value™ of €86.66. GuruFocus considers Legend Biotech to be Possible Value Trap.

Key valuation signals for STU:9LB:

  • FFO per Share:
  • GF Value™: €86.66 vs. price of €20.60 (76.2% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the STU:9LB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Legend Biotech Business Description

Other Exchanges LEGN:USA
Address 2101 Cottontail Lane, Somerset, NJ, USA, 08873
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
75GF Score

Get the complete analysis for STU:9LB

FFO per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.60
Price
€86.66
GF Value